DekaBank Deutsche Girozentrale boosted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 7.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 404,288 shares of the company’s stock after buying an additional 27,094 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Teva Pharmaceutical Industries Limited were worth $13,294,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of TEVA. Cribstone Capital Management LLC increased its stake in Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock valued at $101,000 after buying an additional 100 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its stake in Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after buying an additional 261 shares during the last quarter. Kistler Tiffany Companies LLC increased its stake in Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after buying an additional 1,571 shares during the last quarter. FNY Managed Accounts LLC purchased a new stake in Teva Pharmaceutical Industries Limited during the first quarter valued at $123,000. Finally, Sterling Investment Advisors Ltd. increased its stake in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares during the last quarter. 56.27% of the stock is owned by institutional investors and hedge funds.

Shares of Teva Pharmaceutical Industries Limited (TEVA) opened at 17.30 on Friday. The firm’s market cap is $17.58 billion. Teva Pharmaceutical Industries Limited has a 12-month low of $16.81 and a 12-month high of $55.39. The company has a 50 day moving average price of $29.64 and a 200-day moving average price of $31.56.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same quarter in the prior year, the business earned $1.25 EPS. Teva Pharmaceutical Industries Limited’s revenue was up 12.9% compared to the same quarter last year. Analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Investors of record on Tuesday, August 29th will be paid a dividend of $0.085 per share. The ex-dividend date is Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 1.97%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently -18.95%.

TRADEMARK VIOLATION WARNING: “DekaBank Deutsche Girozentrale Raises Position in Teva Pharmaceutical Industries Limited (TEVA)” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/13/dekabank-deutsche-girozentrale-raises-position-in-teva-pharmaceutical-industries-limited-teva.html.

Several research firms have recently weighed in on TEVA. Jefferies Group LLC reissued a “hold” rating and issued a $26.00 target price (down from $33.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Deutsche Bank AG reissued a “buy” rating and issued a $28.00 target price (down from $43.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Maxim Group reissued a “hold” rating and issued a $35.00 target price on shares of Teva Pharmaceutical Industries Limited in a report on Friday, August 4th. Sanford C. Bernstein downgraded Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $42.00 to $28.00 in a research note on Friday, August 4th. Finally, Barclays PLC reduced their price objective on Teva Pharmaceutical Industries Limited from $38.00 to $23.00 and set an “equal weight” rating for the company in a research note on Monday, August 7th. Three research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $37.69.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.